GB2286528A - Dietary supplement - Google Patents

Dietary supplement Download PDF

Info

Publication number
GB2286528A
GB2286528A GB9403063A GB9403063A GB2286528A GB 2286528 A GB2286528 A GB 2286528A GB 9403063 A GB9403063 A GB 9403063A GB 9403063 A GB9403063 A GB 9403063A GB 2286528 A GB2286528 A GB 2286528A
Authority
GB
United Kingdom
Prior art keywords
composition
phenylalanine
sulphate
mucopolysaccharide
dietary supplement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9403063A
Other versions
GB9403063D0 (en
GB2286528B (en
Inventor
Robert John Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB9403063A priority Critical patent/GB2286528B/en
Publication of GB9403063D0 publication Critical patent/GB9403063D0/en
Publication of GB2286528A publication Critical patent/GB2286528A/en
Application granted granted Critical
Publication of GB2286528B publication Critical patent/GB2286528B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sources of vitamin B3, B5 and/or B6, D-phenylalanine, glucosamine sulphate and optionally mucopolysaccharides such as chrondroitin sulphate and shark cartilage. The composition can provide relief of joint or muscular pain e.g. arthritis.

Description

DIETARY SUPPLEMENT The present invention relates to a dietary supplement having active components which are useful in the relief of joint or muscular pain e.g. in patients suffering from arthritis.
In one aspect the invention provides a composition comprising (a) vitamin B3, B5 and/or B6; (b) a source of D-phenylalanine; and (c) glucosamine sulphate and/or a source thereof, the components of the composition synergistically reducing the pain in joints or muscles when taken by an affected patient as a dietary supplement.
In an alternative aspect the invention provides a method for making a dietary supplement whose active components can synergistically reduce pain in joints or muscles when the composition is taken by an affected patient over an extended period, said process comprising forming into a unit dosage form (a) vitamin B3, B5 and/or B6, (b) a source of D-phenylalanine and (c) glucosamine sulphate and/or one or more mucopolysaccharides.
The above composition comprises as component (a) pantothenic acid or a salt or ester thereof, conveniently the calcium salt of pantothenic acid. This material may be partly or completely replaced by nicotinamide or pyridoxine (vitamins B3 and B6). Calcium pantothenate has been reported to relieve the symptoms of rheumatoid arthritis, but at the relatively high daily dose of 2g (see "The Practitioner", February 1980, pages 208 to 211).
D-phenylalanine has been shown to be effective in the treatment of a variety of chronic pain conditions. It is converted slowly in the body to the L-form. It has been postulated that the D-form of phenylalanine, but not the L-form inhibits a number of enzymes which destroy the body's natural pain-killing materials including the enzymes carboxypeptidase A and enkephalinase. The effect of inhibiting these enzymes is that the endorphins naturally produced within the brain have a longer persistence and are therefore able to exert their natural pain-relieving action for more extended periods of time.
Again, a daily dose of more than 1 gram of DPLA has been recommended in order to achieve the desired pain reduction effect.
Glucosamine sulphate is an aminomonosaccharide which is naturally present in the body and especially articular cartilages. It has been reported to have a better therapeutic ratio for prolonged treatment of inflammatory disorders than indomethacin, but again high oral daily doses are required.
The present invention is based on the unexpected discovery that a dietary supplement containing pantothenic acid or a salt or ester thereof, DPA or DLPA and glucosamine sulphate can produce pain relief when taken at relatively low dosages. For example a suitable tablet formulation may contain the following active ingredients Ingredient Amount Pantothenic Acid 100 mg Shark Cartilage 100 mg DL-Phenylalanine 50 mg Chondroitin Sulphate 50 mg Glucosamine Sulphate 50 mg The above ingredients may be tabletted with conventional tabletting additives, for example dibasic calcium phosphate, potato starch, ethyl cellulose as glazing agent, stearic acid and magnesium stearate. A recommended daily dose of tablets containing the above mentioned active ingredient is 2-6 tablets daily according to need, typically in many cases about 3 tablets daily.
Further ingredients of the above tablets which are at present believed to act synergistically, but whose presence may be optional, include a mucopolysaccharide such as chrondroitin sulphate. That material is a constituent of cartilaginous tissue and has been demonstrated in vitro to inhibit leucocyte elastase which is an enzyme produced by macrophages and found in high concentrations in the blood and synovial fluid of patients with various rheumatic diseases. It can lead to significant alterations in the constitution of proteoglycans and collogen fibres which are fundamental components of cartilaginous tissue. It has been postulated that the action of chrondroitin sulphate in the present tablets is similar to that of glucosamine sulphate, but that the action of the chrondroitin sulphate is sustained, whereas the glucosamine sulphate produces a more rapid but less sustained physiological response.
It is preferred that there should also be present in the composition a further mucopolysaccharide derived from animal cartilage, especially marine cartilage and in particular shark cartilage. This material when used as a dietary additive is also believed to have beneficial effect on the inflammation which is present in arthritic and rheumatic disorders.
The present composition when employed as a dietary supplement may in some patients give relief of pain in arthritis, rheumatism or chronic back pain.

Claims (11)

1. A composition comprising (a) vitamin B3, B5 and/or B6; (b) a source of D-phenylalanine; and (c) glucosamine sulphate and/or a source thereof, the components of the composition synergistically reducing pain in joints or muscles when taken by an affected patient as a dietary supplement.
2. The composition of claim 1, wherein the component (a) is a salt or ester of pantothenic acid.
3. The composition of claim 1, wherein the component (a) is calcium pantothenate.
4. The composition of any of claims 1 to 3, wherein the component (b) is DL-phenylalanine.
5. The composition of any preceding claim, wherein there is further present a mucopolysaccharide.
6. The composition of claim 5, wherein the mucopolysaccharide is chrondroitin sulphate.
7. The composition of claim 5 or 6, wherein there is further present a cartilage-derived mucopolysaccharide.
8. The composition of claim 7, wherein the mucopolysaccharide is shark cartilage.
9. A composition according to any preceding claim, in unit dosage form comprising calcium pantothenate, shark cartilage in a weight approximately equal to that of the calcium pantothenate, and DL phenylalanine, chrondroitin sulphate and glucosamine sulphate each in about half the amount by weight of the calcium pantothenate.
10. A composition according to any preceding claim in the form of tablets.
11. A process for making a dietary supplement whose active components synergistically reduce the pain in joints or muscles when the composition is taken by an affected patient over an extended period, said process comprising forming into a unit dosage form (a) vitamin B3, B5 and/or B6, (b) a source of D-phenylalanine and (c) glucosamine sulphate and/or one or more mucopolysaccharides.
GB9403063A 1994-02-17 1994-02-17 Dietary supplement Expired - Fee Related GB2286528B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9403063A GB2286528B (en) 1994-02-17 1994-02-17 Dietary supplement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9403063A GB2286528B (en) 1994-02-17 1994-02-17 Dietary supplement

Publications (3)

Publication Number Publication Date
GB9403063D0 GB9403063D0 (en) 1994-04-06
GB2286528A true GB2286528A (en) 1995-08-23
GB2286528B GB2286528B (en) 1998-09-16

Family

ID=10750516

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9403063A Expired - Fee Related GB2286528B (en) 1994-02-17 1994-02-17 Dietary supplement

Country Status (1)

Country Link
GB (1) GB2286528B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056404A1 (en) * 1999-03-24 2000-09-28 Kilgowan Limited Formulations for treatment of pain comprising vitamin b12 and phenylanine
WO2000056275A1 (en) * 1999-03-22 2000-09-28 Virbac Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration
WO2001019359A2 (en) * 1999-09-16 2001-03-22 Britannia Pharmaceuticals Limited Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
WO2001074781A1 (en) * 2000-03-21 2001-10-11 Astion Development Aps Chemical complex comprising a substituted pyridine carboxy derivative and a glucosaminoglycan
EP1158972A1 (en) * 1999-01-12 2001-12-05 Seymour Ehrenpreis Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
EP1263418A2 (en) * 1999-06-22 2002-12-11 Joint Juice Incorporated Cartilage enhancing food supplements and methods of preparing the same
WO2003002117A2 (en) * 2001-06-29 2003-01-09 Astion Development A/S Niaciamide and derivatives in combination with aminosugar
US8906966B2 (en) 2006-07-13 2014-12-09 Paul Sherwood Medicaments containing panthenol

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158972A1 (en) * 1999-01-12 2001-12-05 Seymour Ehrenpreis Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
EP1158972A4 (en) * 1999-01-12 2003-05-02 Seymour Ehrenpreis Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
WO2000056275A1 (en) * 1999-03-22 2000-09-28 Virbac Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration
FR2791262A1 (en) * 1999-03-22 2000-09-29 Virbac Sa COMPOSITIONS BASED ON CHONDROITINE AND CHITOSAN FOR THE PROTECTION, TREATMENT OR REPLACEMENT OF CONNECTIVE TISSUES
US6599888B1 (en) 1999-03-22 2003-07-29 Virbac Chondroitin sulphate and chitosan compositions for treating rheumatic disorders
WO2000056404A1 (en) * 1999-03-24 2000-09-28 Kilgowan Limited Formulations for treatment of pain comprising vitamin b12 and phenylanine
EP1263418A2 (en) * 1999-06-22 2002-12-11 Joint Juice Incorporated Cartilage enhancing food supplements and methods of preparing the same
EP1263418A4 (en) * 1999-06-22 2003-03-12 Joint Juice Inc Cartilage enhancing food supplements and methods of preparing the same
WO2001019359A3 (en) * 1999-09-16 2002-10-03 Britannia Pharmaceuticals Ltd Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
GB2355930A (en) * 1999-09-16 2001-05-09 Britannia Pharmaceuticals Ltd Injection of pantothenic acid for relief of pain in joints
WO2001019359A2 (en) * 1999-09-16 2001-03-22 Britannia Pharmaceuticals Limited Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
US8614249B2 (en) 1999-09-16 2013-12-24 Prototype Bioforum Ltd. Medicaments containing pantothenic acid
WO2001074781A1 (en) * 2000-03-21 2001-10-11 Astion Development Aps Chemical complex comprising a substituted pyridine carboxy derivative and a glucosaminoglycan
WO2003002117A2 (en) * 2001-06-29 2003-01-09 Astion Development A/S Niaciamide and derivatives in combination with aminosugar
WO2003002117A3 (en) * 2001-06-29 2003-03-20 Astion Dev As Niaciamide and derivatives in combination with aminosugar
US8906966B2 (en) 2006-07-13 2014-12-09 Paul Sherwood Medicaments containing panthenol

Also Published As

Publication number Publication date
GB9403063D0 (en) 1994-04-06
GB2286528B (en) 1998-09-16

Similar Documents

Publication Publication Date Title
US6645948B2 (en) Nutritional composition for the treatment of connective tissue
US5840715A (en) Dietary regimen of nutritional supplements for relief of symptoms of arthritis
EP1849471B1 (en) Compositions comprising an aminosugar, chondroitin, and S-adenosylmethionine
US6271213B1 (en) Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue
US6136795A (en) Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US5053429A (en) Treating inflammatory pain with methionine
EP1337263B1 (en) A composition of rose hip and fish oil for alleviating joint pain and stiffness
US20050282772A1 (en) New dietary supplement composition for obesity and inflammation
JPH0651626B2 (en) Composition for treating tissue degenerative inflammatory disease
US20010046971A1 (en) Analgesics combined with naturally-occurring chondroprotective agents
EP0855908B1 (en) Dietary regimen of nutritional supplements for relief of symptoms of arthritis
AU2574295A (en) Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases
WO1999062524A1 (en) Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue
GB2286528A (en) Dietary supplement
KR100861430B1 (en) Preparations and Method of Producing the Same
US6838451B1 (en) Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases
AU3438500A (en) Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration
WO2003099013A1 (en) Acetaminophen/non-steroidal anti-inflamatory drug-glucosamine composition
WO2002009725A1 (en) Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases
CA2446615C (en) Nutritional composition for the treatment of connective tissue
JP2004026846A (en) Therapeutic or prophylactic composition for arthralgia
AU2003203346A1 (en) Non-steroidal anti inflammatory drug and glucosamine combination
WO2013108263A1 (en) Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20050217